Molecular Profile Detail

Profile Name KDR act mut
Gene Variant Detail

KDR act mut (gain of function)

Relevant Treatment Approaches VEGFR Inhibitor (Pan) VEGFR2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KDR act mut Advanced Solid Tumor predicted - sensitive VEGFR Inhibitor (Pan) Lucitanib Phase I Actionable In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991). 25193991
KDR act mut Advanced Solid Tumor sensitive VEGFR2 Inhibitor Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655). 19723655
KDR act mut Advanced Solid Tumor sensitive VEGFR2 Inhibitor Sunitinib Preclinical Actionable In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655). 19723655
KDR act mut bladder urothelial carcinoma predicted - sensitive VEGFR2 Inhibitor Sunitinib Phase II Actionable In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593). 20142593
Clinical Trial Phase Therapies Title Recruitment Status